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ABSTRACT 
Bone Morphogenetic Protein-7 (BMP-7) belongs to the transforming growth 
factor-β (TGFβ) family of cytokines has is known to have potent anti-inflammatory 
properties. It has been used in patients to treat osteoporosis clinically and has been 
reported to treat diabetic nephropathy in murine models. Moreover, studies show that 
inflammation is up-regulated in patients with pre-diabetes (PD). We, therefore, 
hypothesize that the administration of BMP-7 will attenuate inflammation in the heart of 
Streptozotocin (STZ)-induced PD mice. In this study, we divided C57Bl/6 mice into three 
groups: CONTROL, PD, and PD+BMP-7. CONTROL mice received intraperitoneal (i.p.) 
injections of Sodium Citrate Buffer while PD and PD+BMP-7 groups received i.p. 
injections of Streptozotocin (STZ) for two days. In addition, PD+BMP-7 mice received 
intravenous injections (i.v.) of BMP-7 (200µg/kg) on the last day of STZ injection and for 
the following two days. Animals were sacrificed 21 days post last injection and 
examined for levels of oxidative stress, inflammatory immune response, apoptosis, 
fibrosis and cardiac function. Our results indicate significant glucose intolerance in PD 
mice (p<0.05), which was attenuated in the PD+BMP-7 group (p<0.05). We also 
observed increased oxidative stress (p<0.001) and secretion of pro-inflammatory 
cytokines (p<0.05), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), in PD mice 
as compared with the controls. PD+BMP-7 mice revealed significant up-regulation of M2 
macrophages (p<0.05) and secretion of anti-inflammatory cytokines (p<0.05), 
interleukin-10 (IL-10) and interleukin-1RA (IL-1RA), as compared to PD mice. This was 
observed with a concomitant down-regulation of pro-inflammatory cytokines, IL-6 and 
TNF-α, as compared to the PD group. Moreover, we observed significantly increased 
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cardiac apoptosis and fibrosis in PD mice (p<0.001) as compared to the control group. 
These observations, however, were down-regulated upon treatment with BMP-7. Lastly, 
analysis of echocardiograms revealed significantly depressed cardiac function in PD 
mice as compared with controls, while the PD+BMP-7 group presented improved 
cardiac function compared to PD mice. In conclusion, our data suggest that treatment 
with BMP-7 is effective in alleviating cardiac inflammation, inhibiting apoptosis, blunting 
cardiac remodeling and improving cardiac function in the hearts of STZ-induced PD 
mice. This reveals the potential of BMP-7 as a therapy in PD patients who present an 
increased inflammatory immune response. 
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“Do not store up for yourselves treasures on earth, where moth and rust destroy, 
and where thieves break in and steal. 
But store up for yourselves treasures in heaven, where neither moth nor rust destroys, 
and where thieves do not break in or steal; 
for where your treasure is, there your heart will be also.” 
– Matthew 6:19-21 
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CHAPTER 1: INTRODUCTION 
Pre-Diabetes  
Diabetes Mellitus (DM) is a condition that affects about 25.8 million people in the 
United States (Blonde, 2012), with the majority of these patients suffering from Type 2 
Diabetes Mellitus (T2DM). T2DM is characterized by insulin resistance despite relatively 
normal production and secretion from pancreatic β-cells. This results in hyperglycemia, 
which leads to increased risk for conditions such as heart failure (D’Souza et al, 2011) 
and nephropathy (Stolar, 2010). It has been shown, however, that even subclinical 
states of hyperglycemia can lead to adverse effects. Impaired fasting glucose (IFG) and 
impaired glucose tolerance (IGT) are markers for Pre-Diabetes (PD), which may affect 
upwards of 35 million people in the U.S (Nielson and Lange, 2005).  PD is classified as 
fasting plasma glucose levels between 100-125 mg/dL and/or glucose levels between 
140-199 mg/dL after a 2-hour glucose tolerance test (Bergman, 2010). It is estimated 
that up to 25% of those with abnormal fasting glucose levels develop full-blown 
diabetes, most within 2.5 years of initial hyperglycemia. Early detection of abnormal 
glucose levels is, thus, of utmost importance as it can prevent further development of 
the disease and complications such as diabetic cardiomyopathy. 
 Inflammation and Cardiomyopathy 
The leading cause of death in diabetics is diabetic cardiomyopathy; however, it 
has been suggested that microvascular complications begin at lower glucose 
concentrations (Stolar, 2010). In fact, impaired glucose tolerance is associated with up 
to 54% greater risk of death due to cardiovascular disease (Saydah et al., 2001). A 
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strong association between oxidative stress and diabetic cardiomyopathy has long been 
established, however, accumulating evidence suggests that inflammation is also 
involved in cardiomyopathy.  
It has been suggested that diabetes may indeed be related to a dysfunction of 
the innate immune response (Pickup, 1998). In fact, pro-inflammatory cytokines, such 
as IL-6 and TNF-α, have been found to be elevated in sera of patients with T2DM and 
IGT (Pickup et al., 2000; Muller et al., 2002). Furthermore, studies have reported that 
administration of IL-6 can stimulate gluconeogenesis and lead to hyperglycemia (Tsigos 
et al., 1997; Stith et al., 1994), which supports that IL-6 may be involved in the evolution 
of PD to full-blown T2DM. In fact, a prospective study suggested that IL-6 levels can act 
as markers of increased risk for the development of T2DM (Pradhan et al, 2001). 
Investigating therapies that target inflammation may, thus, result in treatments that 
attenuate hyperglycemia and associated complications. 
Bone Morphogenetic Protein-7 
BMP-7 belongs to the TGFβ-2 family of cytokines and is found in tissues 
including the thymus, bone marrow, and heart (Bragdon et al., 2010). It has been shown 
to regulate embryonic development as well as the growth, differentiation and apoptosis 
of endothelial, mesenchymal and cardiac cells (Boon et al., 2011). BMP-7 has also 
been shown to inhibit gene expression of cytokines such as TNF-α, IL-6 and MCP-1 
(Chan et al., 2008;Gould et al., 2002). Moreover, our recent study suggests that BMP-7 
may be able to inhibit inflammation specifically by polarizing monocytes into M2 
macrophages in vitro (Rocher et al., 2012). M2 macrophages are a class of 
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macrophages that counteract inflammation by secreting high levels of IL-10 (Mantovani 
et al., 2004). IL-10 is a well-known anti-inflammatory cytokine that inhibits the 
expression of IL-6 and TNF-α from immune cells (Rajasingh et al., 2006). Thus, BMP-7-
mediated up-regulation of IL-10 may be a potential therapy for conditions associated 
with inflammation, such as hyperglycemia. Since BMP-7 circulates in the blood 
(Zeisberg, 2006), it is reasonable to propose that BMP-7 may alleviate inflammation in 
organs typically affected by hyperglycemia. Thus, we investigated the effect of BMP-7 
on inflammation in the PD heart.  
Hypothesis  
In the present study, we hypothesize that: 
I. Administration of BMP-7 will inhibit cardiomyocyte apoptosis and improve cardiac 
function in a mouse model of streptozotocin-induced pre-diabetes.  
II. The decrease in cardiomyocyte apoptosis is due to a BMP-7 mediated increase 
in M2 macrophage population and anti-inflammatory cytokine secretion. 
Aims 
 Aim 1. Determine the effects of exogenous BMP-7 on apoptosis and cardiac 
function in streptozotocin-Induced pre-diabetic cardiomyopathy. 
 Aim 2. Determine the efficacy of which BMP-7 can increase M2 macrophage 
population and thereby decrease inflammation in the Pre-Diabetic heart. 
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CHAPTER 2: MATERIALS AND METHODS 
Streptozotocin-Induced Pre-Diabetes  
C57Bl/6 mice 8-10 weeks old were used in this study and maintained in a 
temperature controlled facility with access to food and water except when fasting for 
experiments. All animal studies were approved by the University of Central Florida 
Institutional Animal Care Use Committee. The mice were divided into three groups; 
Control, Pre-diabetic (PD) and PD+BMP-7 with n=7-10 animals in each group.  
Multiple low doses of STZ (50mg/kg) have been previously used to create a 
T2DM model in rodents (Poucher et al, 2012; Zeng et al, 2012) while single high doses 
of STZ have been used to create T1DM models (Yin et al, 2006). As uncontrolled Pre-
Diabetes has been shown to develop into T2DM, we used a modified low dose of STZ 
to create a PD model.  
Mice in the Control group received intraperitoneal (IP) injections of Sodium 
Citrate Buffer for two consecutive days while the remaining two groups received i.v. 
injections of 50 mg/kg Streptozotocin (STZ) prepared in the vehicle. The PD+BMP-7 
group received one i.v. injection of BMP-7 (200 µg/kg) on the second day of STZ 
induction and for the next two consecutive days. 
Glucose Levels and Glucose Tolerance Test 
Blood glucose levels were measured 7 and 21 days after the last injection using 
an OneTouch Ultra Mini glucose meter. On the 20th day, all groups underwent a 
glucose tolerance test. The mice were then fasted for 6 hours and their initial glucose 
levels were measured via tail-vein puncture. Intraperitoneal injections of 1g/kg glucose 
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were administered and blood glucose levels were checked every 30 minutes for a total 
of 120 minutes post-glucose injection. 
Tissue Processing 
Mouse hearts were harvested then washed with phosphate buffer saline (PBS) 
and cut transversely into two halves. The top half was kept in RNA Later solution for 24 
hours in 4°C, decanted and placed in -80°C for future molecular studies. The apical half 
of the heart was kept in 4% paraformaldehyde at 4°C for 24 hours. The hearts were 
then rinsed with PBS three times for five minutes each, processed utilizing the Leica 
TP1020 tissue processing system and then embedded in paraffin wax with Tissue Tek 
TEC machines. Paraffin-embedded hearts were then sectioned into 5µm sections and 
placed onto Colorfrost Plus slides (Fischer Cat. #12-550-17).  
Immunohistochemistry 
Heart sections were deparaffinized and rehydrated as previously described. 
Heat-induced epitope retrieval was performed on the tissues for 20 minutes. Sections 
were then washed for five minutes three times with PBS and blocked with 10% goat 
serum (Vector Labs Cat. #S-1000) for one hour. Heart sections were incubated in 
primary antibody (CD206 [1:50, Abcam Cat. #ab64693], IL-10 [1:100, Abcam Cat. 
#ab33471], TNF-alpha [1:100, Abcam Cat. #ab6671], Il-6 [1:100, Abcam Cat. #ab6672]) 
prepared in 10% goat serum overnight at 4°C. The sections were then washed for five 
minutes three times in PBS and incubated with secondary antibody (goat anti-rabbit 488 
[1:50, Invitrogen Cat. #A11008 ], goat anti-rabbit 568 [1:50, Invitrogen Cat. #A11011 ] or 
goat anti-rat 594 [1:50, Invitrogen Cat. #A11007]) for one hour at room temperature. 
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Finally, the sections were washed for five minutes three times with PBS, the nuclei 
stained with DAPI (Vector Labs Cat. #H-1200) and images taken an Olympic IX-70 
fluorescent and confocal microscope. 
Enzyme Linked Immunosorbent Assay (ELISA)  
 On Day 21, mice were sacrifice and blood samples were collected in EDTA tubes 
(BD Microtainer, Cat. # REF 365973). Blood samples were centrifuged at 13,000 rpm 
for 10 minutes to isolate the sera, which were collected and stored at -20°C until 
needed. Commercial ELISA kits were used to determine levels of IL-10 (Raybiotech, 
Cat. #ELM-IL10-001), IL-1RA (Raybiotech, Cat. #ELM-IL1RA-001), TNF-α (Raybiotech, 
Cat. #ELM-TNFalpha-001), and IL-6 (Raybiotech, Cat. #ELM-IL6-001) and were 
followed according to manufacturers’ instructions. 
Terminal Deoxynucleotidyl Transferase dUTP-Mediated Nick-End Labeling Assay 
 Heart sections were deparaffinized and rehydrated as previously described. The 
tissues were then incubated with proteinase-K (25 µg/ml) prepared in 100 mM Tris-HCL 
for 15 minutes at room temperature. Terminal deoxynucleotidyl transferaste dUTP-
mediated nick-end labeling (TUNEL) staining was then performed using a commercial 
cell death detection kit (Roche, Cat. #12156792910) according to manufacturer 
instructions. Sections were rinsed three times with PBS for five minutes each, the nuclei 
stained with DAPI and images taken with an Olympus IX-70 fluorescent and confocal 
microscope. Four images per section were analyzed by calculating the percent of 
apoptotic nuclei using NIH ImageJ software. In brief, cells with TUNEL positive (red) 
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nuclei that merged with DAPI (blue) were counted, divided by total nuclei and expressed 
as a percent. 
Western Blot 
  Heart tissues were sonicated in RIPA buffer and centrifuged at 13,000g for 10 
minutes. Supernatants were collected, prepared for protein quantification using Bio-Rad 
Protein Assay Dye (Bio-Rad Cat. #500-0006) and protein concentration was determined 
using a Biorad 680 microplate reader. Samples were run on either a 10% or 12% 
sodium-dodecyl sulfate polyacrylamide gel at 150V for one hour and then transferred 
onto a PVDF membrane (Bio-Rad Cat. #162-0177) at 15V for 35-60 minutes using a 
Trans-Blot Semi-dry transfer Cell. Blocking with 5% milk prepared in TBST was 
performed for one hour,  membranes washed for five minutes three times with TBST 
and then incubated with primary antibody (p-AKT [1:1000, Cell Signaling Cat. #4058S], 
AKT [1:1000, Cell Signaling Cat. #4685S], PTEN [1:1000, Cell Signalling Cat. #9559S], 
p-PTEN [1:1000, Cell Signaling Cat. #9554S], MnSOD [1:5000, AbCam Cat. #ab13533] 
or Beta Actin [1:1000, Cell Signalling Cat. #4967L]) for one hour at room temperature or 
overnight at 4°C. The membranes were then washed for five minutes three times with 
TBST and incubated with secondary antibody (goat anti-rabbit [1:1000 or 1:5000, Cell 
Signaling Cat. #7074S]) for one hour at room temperature. Finally, the membranes were 
washed for five minutes three times with TBST, incubated with ECL for 2 minutes and 
then visualized via radiography. 
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Masson’s Trichrome Staining 
 Heart sections were deparaffinized, rehydrated and subsequently stained for 
interstitial and vascular fibrosis through Masson’s Trichrome staining as previously 
described (Singla et al., 2007). Fibrotic area (mm2) was assessed using the ImageJ 
software to measure collagen deposition (blue); interstitial fibrosis was calculated by 
measuring collagen within three areas of interstitial tissue per section while vascular 
fibrosis was measured as a ratio of vessel collagen deposition over total vessel area x 
100% in six vessels per section.  
Dihydroethidium Staining 
Levels of radical oxygen species (ROS) were assessed by staining heart 
sections with dihydroethidium (DHE). In brief, the sections were deparaffinized and 
rehydrated as previously described (Singla et al., 2007) and then stained with 1 μM/ml 
DHE for 25 minutes at room temperature. Random images of each section were taken 
using an Olympic IX-70 fluorescent and confocal microscope. DHE intensity was then 
measured in each image using NIH ImageJ software and the average corrected 
integrated density was calculated for each animal.  
Echocardiography 
On Day 21, all mice underwent two-dimensional (2D) transthoracic 
echocardiography in order to assess their cardiac function. The animals were 
anesthetized with 2% isofluorane and laid on a heating pad. A 5500 Ultrasound System 
with a 15-6L Hockey stick transducer was used to take M-mode images of the left 
ventricle from which end diastolic volume (EDV), end systolic volume (ESV), ejection 
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fraction (EF%), left ventricular internal dimension-diastole (LVIDd), left ventricular 
internal dimension-systole (LVIDs), and fractional shortening (FS%) were measured. 
Following echocardiography, the mice were euthanized through cervical dislocation. 
The hearts were harvested, washed with PBS, separated with a transverse incision and 
either placed in formalin for sectioning or RNA Later for molecular analyses. Blood 
samples were collected in EDTA tubes (BD Microtainer Cat. # REF 365973) and kept in 
-20°C for future use.  
Statistical Analysis 
All samples were analyzed using one-way analysis of variance (ANOVA) 
followed by Tukey Test. Values are presented as a mean ± SEM with a p<0.05 
considered to be statistically significant.  
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CHAPTER 3: RESULTS 
Exogenous BMP-7 Improves Glucose Tolerance in Pre-Diabetic Mice  
Glucose levels were measured via tail-vein puncture on days 7 and 21 after last 
injection. STZ treatment was effective in elevating the blood glucose levels of PD mice 
on both Day 7 and Day 21 as compared to the controls (Figure 1A-B). PD+BMP-7 mice, 
however, had reduced glucose levels as compared to the PD group. Impaired glucose 
tolerance is a marker for PD (Bergman, 2010), thus, we performed glucose tolerance 
tests on Day 20 to evaluate the extent to which the mice can metabolize glucose. 
Results show decreased glucose tolerance in the PD group at both 30 and 120 minutes 
(Figure 1C-D). PD+BMP-7 mice had reduced glucose levels at the 30 minute time point 
and statistically improved glucose tolerance at the 120 minute time point as compared 
to the PD group.  
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Figure 1. Effects of BMP-7 on glucose tolerance in PD mice. Glucose levels were 
measured via tail-vein puncture on days 7 and 21 after last injection (n=6-8 animals per 
group). (A,B) Pre-diabetic mice had significantly elevated glucose levels on both days 7 
and 21 as compared to Control mice (*p<0.05) while treatment with BMP-7 significantly 
decreased glucose levels as compared to the PD group (#p<0.05). On day 20, mice 
underwent a glucose tolerance test (n=6-8 animals per group). Glucose levels at time 
points 30 and 120 minutes are shown. (C,D) The PD group resulted in impaired glucose 
tolerance as compared to the Control group (p<0.05). BMP-7 treatment resulted in 
increased glucose tolerance as compared to the PD group, which reached statistical 
significance 120 minutes post glucose injection (p<0.05).  
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BMP-7 Increases M2 Macrophages and Ameliorates Inflammation in the Heart 
In order to evaluate the effects of BMP-7 on inflammation in PD mice, heart 
sections were incubated with antibodies against CD206, a marker for M2 macrophages. 
No significant difference was seen in M2 macrophage population between Control and 
PD mice; however, mice treated with BMP-7 showed a significant elevation in M2 
macrophage population as compared to the PD group (Figure 2A-P).  
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Figure 2. Effects of BMP-7 on immune cell populations in the PD heart. Sections were 
stained for CD206, a marker for M2 macrophages depicted in red (A,F,K). Sarcomeric 
α-actin was stained and is shown in green (B,G,L), while nuclei were stained in blue 
with DAPI (C,H,M) (n=4 animals per group). A merge of the three pictures is shown 
(D,I,N) along with a magnified view (E,J,O). There was no difference in M2 macrophage 
populations between Control and PD mice (P), however, mice in the PD+BMP-7 group 
had significantly elevated levels of M2 macrophages as compared to the PD group 
(*p<0.05).  
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To determine the effects of increased M2 macrophages within the hearts of PD 
mice treated with BMP-7, we analyzed the levels of cytokine expression in heart tissues 
and in serum samples through immunohistochemistry and ELISA, respectively. 
Although not statistically significant, quantitative analyses of stained tissues showed 
decreased levels of IL-10 in PD mouse hearts as compared to the controls (Figure 3A-
P). Furthermore, treatment with BMP-7 resulted in an observable increase in IL-10. 
Analyses of serum samples revealed a statistically significant decrease of IL-10 in PD 
mice, which was significantly elevated in mice treated with BMP-7 (Figure 3Q). In 
addition to IL-10, we also measured the levels of another anti-inflammatory cytokine, IL-
1RA, in serum samples. Results indicated significantly decreased levels of IL-1RA in PD 
(*p<0.05) mice as compared to the controls (Figure 3R). Analyses also revealed that 
treatment with BMP-7 was able to significantly increase levels of the anti-inflammatory 
cytokine as compared to the PD group (#p<0.05).  
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Figure 3. BMP-7 regulates inflammation in the PD heart. Heart tissues were stained for 
IL-10 in red (A,F,K) (n=5 samples per group), sarcomeric α-actin in green (B,G,L) and 
nuclei blue (C,H,M). Merged (D,I,N) and magnified (E,J,O) pictures are also shown. PD 
mice had noticeably reduced levels of IL-10 as compared to the controls. Although not 
statistically significant, BMP-7 treatment observably increased IL-10 levels as compared 
to the PD group. (Q) Serum samples were analyzed for IL-10 expression using an 
ELISA kit (n=4-5 samples). PD mice had significantly (*p<0.05) decreased IL-10 in the 
serum as compared to the controls. Treatment with BMP-7 was effective in significantly 
(#p<0.05) restoring levels of IL-10. (R) Serum levels of IL-1RA were also measured 
using a commercial ELISA kit (n=5-7 samples). PD mice had significantly (*p<0.05) 
reduced levels of IL-1RA as compared to the controls, whereas PD+BMP-7 mice had 
significantly (*p<0.05) up-regulated levels of the cytokine as compared to the PD group. 
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In order to determine the effects of increased IL-10 in PD+BMP-7 mice, we 
measured levels of pro-inflammatory cytokines, TNF-α and IL-6. Analysis of heart 
sections showed significantly increased levels of TNF-α in PD mice as compared to the 
controls (Figure 4A-P). This increase was attenuated in the PD+BMP-7 group, which 
experienced significantly decreased levels of the pro-inflammatory cytokine as 
compared to the PD mice. Quantitative analyses revealed a similar trend, although not 
statistically significant, in our serum ELISA samples (Figure 4Q).  
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Figure 4. BMP-7 inhibits TNF-alpha in PD mice. Heart sections were stained for TNF-α 
in red (A,F,K), sarcomeric α-actin in green (B,G,L) and nuclei in blue (C,H,M) (n=4-5 
animals per group). Merged (D,I,N) and magnified (E,J,O) pictures are also shown. PD 
mice had significantly increased levels of the pro-inflammatory cytokine (P) as 
compared to the Control group (*p<0.05). BMP-7 treatment resulted in significantly 
decreased levels of the cytokine as compared to the PD group (#p<0.05). (Q) Serum 
samples from mice analyzed to detect levels of TNF-α through an ELISA kit (n=5-7 
samples per group). Although not statistically significant, there was an observable 
increase in the pro-inflammatory cytokine in PD mice. Levels of TNF-α in PD+BMP-7 
mice were observably lower than those in the PD group and followed the trend seen in 
the tissue staining. 
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Levels of another pro-inflammatory cytokine, IL-6, were also measured in heart 
tissues and serum samples. Quantitative analyses of the stained tissues revealed 
increased levels of IL-6 in PD hearts, which was significantly alleviated with BMP-7 
treatment (Figure 5 A-P). Our IL-6 ELISA results follow a similar trend. Serum samples 
from PD mice had increased levels of IL-6 as compared to the controls, while PD+BMP-
7 had significantly decreased levels compared to PD mice (Figure 5Q). 
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Figure 5. BMP-7 inhibits IL-6 in PD mice. Mouse tissues were stained for IL-6 in red 
(A,F,K), sarcomeric α-actin in green (B,G,L) and nuclei in blue (C,H,M) (n=7-8 samples 
per group). Merged (D,I,N) and magnified (E,J,O) pictures are also shown. (P)PD mice 
had significant (*p<0.05) up-regulation of the pro-inflammatory cytokine as compared to 
the control mice. BMP-7 treatment effectively (#p<0.05) ameliorated inflammation in the 
heart as compared to the PD mice. (Q)Serum samples were analyzed for IL-6 
expression using a commercial ELISA kit (n= 4-6 samples per group). PD mice had up-
regulated (*p<0.05) levels of IL-6 as compared to the controls. Treatment with BMP-7 
was effective (#p<0.05) in inhibiting IL-6 levels as compared to PD mice. 
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BMP-7 Inhibits Apoptosis in Pre-Diabetic Mice by Regulation PTEN and AKT 
In order to assess the role of BMP-7 in cardiomyocyte apoptosis in vivo, we 
performed TUNEL staining on mouse heart sections (Figure 6A-J). Quantitative 
analyses reveal increased apoptotic nuclei in the hearts of PD mice as compared to the 
controls. Furthermore, our results show that treatment with BMP-7 significantly 
alleviated apoptosis as compared to untreated mice.  
To further understand how BMP-7 inhibits apoptosis, we assessed the 
expression of a cell cycle regulator and tumor suppressor, phosphatase and tensin 
homolog (PTEN). In order to assess the effect of BMP-7 on PTEN, we measured the 
expression of phosphorylated PTEN in mouse heart homogenates (Figure 6K). 
Quantitative analyses of western blots show significantly up-regulated expression of 
phosphorylated PTEN in PD mice as compared to the controls. PD+BMP-7 mice 
showed significantly decreased levels of phosphorylated PTEN as compared to the PD 
mice. PTEN is a negative regulator for AKT, a survival protein. In order to determine the 
effects of BMP-7 on levels of p-AKT in PD mice, we performed western blots on mouse 
heart homogenates (Figure 6L). Quantitative analyses of results show that levels of p-
AKT are down-regulated in PD mice, while treatment with BMP-7 significantly up-
regulated levels of the survival protein.  
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Figure 6. BMP-7 inhibits apoptosis in the PD heart. Heart sections were assessed for 
apoptotic nuclei using TUNEL staining (A,D,G) (n=5-6 samples per group). Total nuclei 
were stained with DAPI in blue (B,E,H) and the images were merged (C,F,I). PD mice 
had a significantly (*p<0.001) higher percent of apoptotic nuclei (J) as compared to the 
controls. BMP-7 treatment was successful in reducing (#p<0.001) the percent of 
apoptotic nuclei as compared to the PD group. Heart samples were also analyzed for 
PTEN using WB (n=5-6 samples per group). Quantitative analyses show significantly 
(*p<0.05) increased phospho-PTEN (K) in PD hearts as compared to the controls. 
PTEN was significantly (#p<0.05) down-regulated in PD+BMP-7 hearts. Heart samples 
were also assessed for the expression of activated AKT (n=5-6 samples per group). PD 
mice had significantly (*p<0.05) reduced levels of phospho-AKT as compared to the 
controls (L). BMP-7 was effective (#p<0.05) in up-regulating the activation of AKT as 
compared to the PD group.  
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BMP-7 Ameliorates Cardiac Remodeling in Pre-Diabetic Mice 
In order to determine the effect of BMP-7 on cardiac fibrosis in STZ-induced PD 
mice, we performed Masson’s Trichrome staining on heart sections (Figure 7A-G). 
Quantitative analyses show that both interstitial fibrosis and vascular fibrosis are 
significantly up-regulated in PD mice, while mice treated with BMP-7 had significantly 
down-regulated collagen deposition within the heart.  
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Figure 7. BMP-7 attenuates cardiac remodeling in the PD heart. Hearts were stained 
for interstitial fibrosis (A,B,D) and vascular fibrosis (B,C,E) using Masson’s Trichrome 
staining (n=7-9 samples per group). PD mice showed increase (*p<0.001) in both 
interstitial (F) and vascular (G) fibrosis as compared to the controls. BMP-7 was 
effective (#p<0.05) in blunting both interstitial and vascular collagen deposition as 
compared to the PD group. 
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BMP-7 Reduces Cardiac Oxidative Stress through the Up-Regulation of MnSOD  
In order to assess the effect of BMP-7 cardiac oxidative stress in PD mice, tissue 
sections were stained with dihydroethidium as previously described (Singla et al., 2007). 
PD hearts revealed elevated levels of reactive oxygen species as compared to the 
controls (p<0.001), however, hearts from the PD+BMP-7 group had significantly 
reduced levels of ROS as compared to PD mice (Figure 8 A-J). Heart tissues were also 
analyzed for the expression of MnSOD. Quantitative analysis of our western blots 
revealed significantly down-regulated expression of MnSOD in PD mice as compared to 
controls (Figure 8K). Treatment with BMP-7, however, was successful in significantly 
up-regulating the expression of MnSOD as compared to the PD group. 
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Figure 8. Effects of BMP-7 on cardiac oxidative stress. Heart sections were stained for 
ROS using dihydroethidium (red) as depicted in red (A,D,G). Nuclei were stained with 
DAPI in blue (B,E,H) and the two images were merged (C,F,I). PD hearts revealed 
significant up-regulation of ROS levels (J) as compared to the controls (*p<0.001), 
however, treatment with BMP-7 effectively decreased levels of ROS as compared to PD 
group (#p<0.001) (n=6 animals per group). MnSOD levels were also assessed in heart 
tissues via western blot (n=5 animals per group). PD hearts resulted in decreased 
expression of MnSOD (K) as compared to the controls (*p<0.05).  Levels of MnSOD 
were significantly up-regulated in PD+BMP-7 hearts as compared to those in pre-
diabetic mice (#p<0.05). 
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Exogenous BMP-7 Improves Cardiac Function in Pre-Diabetic Mice 
To assess the effect of BMP-7 on overall cardiac function in PD mice, the 
animals underwent echocardiography. Analyses shows significantly decreased ejection 
fraction (EF%) and fractional shortening (FS%) in mice treated with STZ (Figure 9A-B). 
Treatment with BMP-7 was able to restore cardiac function and significantly improve 
EF% and FS% as compared to PD mice.  
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Figure 9. BMP-7 improves cardiac function in PD mice. (A,B) Echocardiography was 
performed to assess cardiac function (n=6-9 samples per group). PD mice had 
significantly (*p<0.001) depressed ejection fraction and fractional shortening as 
compared to the control mice. Treatment with BMP-7 was able to significantly 
(#p<0.001) restore cardiac function and resulted in improved ejection fraction and 
fractional shortening as compared to the PD group. 
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CHAPTER 4: DISCUSSION  
Diabetes Mellitus (DM) affects millions of people in the U.S. and is associated 
with increased risk for cardiovascular disease (D’Souza et al, 2011). It has been 
suggested that DM involves the innate immune system (Pickup, 1998) that leads to 
increased pro-inflammatory cytokines. Studies indeed support the role of inflammation 
in DM, however, even glucose concentrations below the diagnostic criteria for diabetes 
can up-regulate pro-inflammatory cytokines and initiate microvascular damage (Stolar, 
2010; Pickup et al., 2000; Muller et al., 2002). BMP-7 has been reported to have potent 
anti-inflammatory properties (Chan et al., 2008;Gould et al., 2002). In this study, we 
investigate the effects of BMP-7 on inflammation in the Streptozotocin-induced PD 
heart.  
PD is characterized by impaired fasting glucose and/or impaired glucose 
tolerance (Nielson and Lange, 2005). Mice in this study were made PD by injections 
with STZ and a 2-hour glucose tolerance test was performed to assess their reactions to 
glucose. Our results indicate that two hours post glucose injection, the PD group still 
presented elevated glucose levels as compared to the control mice. This suggests that 
the PD group were less able to metabolize glucose and exhibited glucose intolerance. 
Interestingly, the PD+BMP-7 group had improved glucose tolerance, and were better 
able to clear glucose as compared to the PD group.  
It has been suggested that DM is actually a disease of the innate immune 
response (Pickup, 1998). In this study, analyses show that PD mice did not exhibit a 
significantly different population of M2 macrophages in the heart as compared to the 
control group. The PD+BMP-7 group, however, showed significantly increased M2 
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macrophages as compared to the PD group. Our recent study found that human 
monocytes treated with BMP-7 are able to polarize into M2 macrophages in vitro 
(Rocher et al., 2012). Considering this previous report, it is likely that BMP-7 up-
regulates anti-inflammatory macrophage population in the PD heart by promoting the 
polarization of monocytes into M2 macrophages.  
M2 macrophages are a class of immune cells that alleviate inflammation by 
secreting anti-inflammatory cytokines, such as IL-10 (Laskin, 2009). Studies suggest 
that IL-10 has a role in modulating inflammation by regulating levels of pro-inflammatory 
cytokines (Moore et al, 1993). We found decreased IL-10 levels in PD mice in both the 
heart tissue and serum, while BMP-7 treatment significantly increased serum levels of 
IL-10. We also determined that treatment with BMP-7 increases levels of IL-1RA, 
another anti-inflammatory cytokine, in the serum.  
The anti-inflammatory properties of BMP-7 have been previously shown in 
various cell types. Gould et al. showed depressed levels of pro-inflammatory cytokines, 
TNF-α and IL-6, in proximal tubular epithelial cells treated with BMP-7. Furthermore, 
Chan et al. showed that human mesangial cells treated with pIgA expressed reduced 
levels of inflammation when pre-incubated with BMP-7. In this study, we found that 
treatment with BMP-7 attenuated pro-inflammatory cytokines, TNF-α and IL-6, both in 
the heart and serum. The inhibition of IL-6 may possibly help to alleviate PD 
hyperglycemia. Clinical and in vivo studies have shown that IL-6 stimulates 
gluconeogenesis and contributes to elevated glucose levels (Tsigos et al., 1997; Stith et 
al., 1994). These reports support the potential of BMP-7 to lower glucose levels and 
protect the PD heart from inflammation by regulating cytokine levels. 
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In addition to its role as a pro-inflammatory cytokine, TNF-α has also been shown 
to cause cardiomyocyte apoptosis in vitro (Dhingra et al., 2011). By binding to its 
receptors, TNF-α initiates the apoptotic cascade by triggering caspase-3 (Dhingra et al., 
2011). Studies have shown that cardiomyocyte apoptosis is up-regulated in diabetic 
patients (Chowdhry et al., 2007) as well as in Streptozotocin models of diabetes (Li et 
al., 2007). Furthermore, a study has shown that bone morphogenetic proteins are able 
to inhibit apoptosis in rat cardiomyocytes in vitro (Izumi et al., 2001). Quantitative 
analyses of our TUNEL staining aligned with previous reports and showed increased 
percentage of apoptotic nuclei in PD hearts as compared to the controls. BMP-7 
attenuated cardiac apoptosis as compared to the PD group, correlating to the in vitro 
data obtained by Izumi et al. It has been suggested that TNF-α-induced cardiomyocyte 
apoptosis can be mediated by anti-inflammatory cytokine, IL-10 (Dhingra et al., 2011). 
Since our results above indicated elevated levels of IL-10 in the PD+BMP-7 group, it is 
reasonable that BMP-7 may decrease apoptosis in the PD heart through IL-10 
facilitated reduction of TNF-α.  
We also investigated the effects of BMP-7 on proteins, Akt and PTEN. Akt is a 
known pro-survival protein that is regulated by tumor suppressor, PTEN. In this study, 
we found elevated levels of phosphorylated-pTEN (p-PTEN) in PD mouse hearts as 
compared to controls, which was observed with a concomitant decrease in levels of 
phosphorylated Akt (p-Akt). BMP-7 treatment was effective in inhibiting the activation of 
the tumor suppressor in the heart and up-regulating levels of p-Akt as compared to PD 
mice. A previous study has shown decreased levels of p-Akt in STZ models of diabetes 
(Jesmin, 2006). Furthermore, it is known that the over-expression of PTEN promotes 
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apoptosis in cardiomyocytes (Schwartzbauer and Robbins, 2001). Therefore, it is likely 
that BMP-7 blunts apoptosis in the PD heart by down-regulating the activation of PTEN 
and increasing the expression of p-AKT. Interestingly, a study suggested that PTEN 
knock-out mice are resistant to STZ-induced diabetes. Kurlawalla et al. proposed that 
PTEN decreases insulin sensitivity and may be a potential target for new diabetic 
therapies. In conjunction with our glucose data presented above, it is possible that 
BMP-7 may work to alleviate hyperglycemia by increasing insulin sensitivity through the 
inhibition of p-PTEN.  
To further assess the anti-apoptotic effects of BMP-7 in the PD heart, we 
investigated its role in cardiac remodeling. It is known that following injury, 
cardiomyocyte apoptosis results in collagen deposition and fibrosis in the heart.  We 
observed significantly increased levels of interstitial and vascular fibrosis in PD mice as 
compared to the controls. This aligns with a study which revealed that cardiac 
remodeling occurs during the PD state (D’Souza et al., 2011). The anti-fibrotic 
properties of BMP-7 have already been shown in the diabetic kidney (Boon et al., 2011). 
In this current study, we found that cardiac fibrosis is significantly attenuated upon 
treatment with BMP-7. This suggests that BMP-7 may be able to inhibit cardiac 
remodeling in the PD heart.  
It is well known that hyperglycemia is associated with oxidative stress. In fact, we 
have previously shown that treatment with STZ results in significant up-regulation of 
reactive oxygen species (ROS) within the heart (Neel and Singla, 2011). In this study, 
we also show elevated levels of oxidative stress in the hearts of STZ-treated mice. 
Quantitative analysis showed that BMP-7 significantly reduced ROS as compared to the 
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PD group. This suggests that BMP-7 may promote antioxidant activity in the PD heart. 
To determine the mechanism by which BMP-7 ameliorated oxidative stress, we 
analyzed heart tissue for the expression of MnSOD, a well-known antioxidant. 
Quantitative analyses of our western blots showed decreased levels of MnSOD in PD 
mice, while mice treated with BMP-7 had significantly increased levels of the 
antioxidant. This aligns with a previous report by Xu et al. in which cardiomyocytes 
transfected with BMP-7 revealed increased levels of MnSOD activity. This up-regulation 
in antioxidant activity was observed with a concomitant decrease in malondialdehyde 
content, which suggests that BMP-7 may protect the heart from oxidative stress by 
attenuating lipid peroxidation. 
Lastly, we investigated the effects of BMP-7 on cardiac function. Although DM is 
highly associated with heart failure, it has been shown that cardiac dysfunction can 
occur even during PD (Mizushige et al., 2000). In this study, we found depressed 
cardiac function in PD mice as compared to the controls. We found that treatment with 
BMP-7 was able to improve overall cardiac function as compared to the PD mice. Taken 
in conjunction with our fibrosis data above, it is likely that BMP-7 may improve cardiac 
function by preventing cardiac remodeling in the PD heart. 
In conclusion, the data presented in this study suggests that BMP-7 treatment 
may inhibit apoptosis, decrease remodeling and improve cardiac function in the PD 
heart. Furthermore, this study suggests that the cardio-protective effects of BMP-7 lie in 
its ability to promote the polarization of monocytes into M2 macrophages and thereby 
reduce inflammation in the STZ-induced PD heart.  
33 
Acknowledgements 
The authors would like to thank Reetu Singla for her ELISA work and Latifa S. 
Abdelli for her assistance in obtaining confocal images. 
  
34 
LIST OF REFERENCES 
Bardini G, Cresci B, Dicembrini I, Rotella CR (2010) Inflammation markers and 
metabolic characteristics of subjects with 1-h plasma glucose levels. Diabetes 
Care 33:411-413. 
Bergman M (2010) Inadequacies of absolute threshold levels for diagnosing 
Prediabetes. Diabetes Metab Res Rev 26: 3–6. 
Blonde L (2012) Benefits and risks for intensive glycemic control in patients with 
diabetes mellitus. Am J Med Sci 343:17-20. 
Bragdon B, Moseychuk O, Saldanha S, King D, Julian J, Nohe A (2010) Bone 
Morphogenetic Proteins: A critical review. Cell Signal 23:609-620. 
Boon MR, van der Horst G, van der Pluijm G, Tamsma T, Smit J, Rensen P (2011) 
Bone morphogenetic protein 7: A broad-spectrum growth factor with multiple 
target therapeutic potency. Cytokine Growth Factor Rev 22:221-229. 
Chan WL, Leung JCK, Chan LYY, Tam KY, Tang SCW, Lai KN (2008) BMP-7 protects 
mesangial cells from injury by polymeric IgA. Kidney Int 74:1026-1039. 
Chowdhry MF, Vohra HA, Galinanes M (2007) Diabetes increases apoptosis and 
necrosis in both ischemic and nonischemic human myocardium: role of caspases 
and poly-adenosine diphosphate-ribose polymerase. J Thorac Cardiovasc Surg 
134:124-131. 
Dhingra S, Bagchi AK, Ludke AL, Sharma AK, Singal PK (2011) Akt regulates IL-10 
mediated suppression of TNFα-induced cardiomyocyte apoptosis by upregulating 
Stat3 phosphorylation. Plos One 6:e25009. 
35 
D’Souza A, Howarth F, Yanni J, Dobryznski H, Boyett M, Adeghate E, Bidasee K, Sing 
J (2011) Left Ventricle Structural Remodelling in the Prediabetic Goto–Kakizaki 
Rat. Exp Physiol 96:875–888. 
Gould SE, Day M, Jones SS, Dora H (2002) BMP-7 regulates chemokine, cytokine, and 
hemodynamic gene expression in proximal tubule cells. Kidney International 
61:51–60. 
IIzumi M, Fujio Y, Kunisada K, Negoro S, Tone E, Funamoto M, Osugi T (2001) Bone 
Morphogenetic Protein-2 Inhibits Serum Deprivation-induced Apoptosis of 
Neonatal Cardiac Myocytes through Activation of the Smad1 Pathway. J Biol 
Chem 276:31133-31141. 
Jesmin S, Zaedi S, Shimojo N, Iemitsu M, Masuzawa K, Yamaguchi N, Mowa CN, 
Maeda S, Hattori Y, Miyauchi T (2007) Endothelin antagonism normalizes VEGF 
signaling and cardiac function in STZ-induced diabetic rat hearts. Am J Physiol 
Endocrinol Metab 292:E1030–E1040. 
Kurlawalla-Martinez C, Stiles B, Wang Y, Devaskar S, Kahn B and Wu H (2005) Insulin 
Hypersensitivity and Resistance in Streptozotocin-Induced Diabetes in Mice 
Lacking PTEN in Adipose Tissue. Mol and Cell Biol 25:2498-2510. 
Laskin DL Macrophages and Inflammatory Mediators in Chemical Toxicity:A Battle of 
Forces. (2009) Chem Res Toxicol 22:1376-1385. 
Li Z, Zhang T, Dai H (2007) Involvement of endoplasmic reticulum stress in myocardial 
apoptosis of streptozocin-induced diabetic rats. J Clin Biochem Nutr 41:58-67. 
36 
Mantovani A, Sica A, Sozzani S, Allavena P, Vecci A, Locati M (2004) The chemokine 
system in diverse forms of macrophage activation and polarization. Trends 
Immunol 25:677-686. 
Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, Matsuo H (1993) 
Alteration in left ventricular diastolic filling and accumulation of myocardial 
collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. 
Circulation 101: 899–907.  
Moore KW, O’Garra A, de Waal Malefytqq R, Vieira P, Mosmann TR (1993) Interleukin-
10. Annu Rev Immunol 11:165-190. 
Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, Giani G, 
Illig T, Thorand B, Kolb H (2002) Impaired glucose tolerance is associated with 
increased serum concentrations of interleukin 6 and co-regulated acute-phase 
proteins but not TNF-α or its receptors. Diabetologia 45:805-812. 
Neel S and Singla DK (2011) Induced pluripotent stem (iPS) cells inhibit apoptosis and 
fibrosis in streptozotocin-induced diabetic rats. Mol Pharm 8:2350-2357. 
Nielson C and Lang T (2005) Blood glucose and heart failure in nondiabetic patients. 
Diabetes Care 28: 607–611. 
Pickup JC and Crook MA (1998) Is type II diabetes mellitus a disease of the innate 
immune system? Diabetologia 41:1241-1248. 
Pickup JC, Chusney GD, Thomas SM, Burt D (2000) Plasma interleukin-6, tumour 
necrosis factor α and blood cytokine production in type 2 diabetes. LifeSci 
67:291-300. 
37 
Poucher SM, Cheetham S, Francis J, Zinker  B, Kirby M, Vickers SP (2012) Effects of 
saxagliptin and sitagliptin on glycaemic control and pancreatic beta cell mass in 
streptozotocin-induced mouse model of type 2 diabetes. Diabetes Obes 
Metab.10:918-926. 
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, 
Interleukin 6, and Risk of developing Type 2 Diabetes Mellitus. J Am Med Assoc 
286:327-334. 
Rajasingh J, Bord E, Luedemann C, Asai J, Hamada H, Thorne T, Qin G, Goukassian 
D, Zhu Y, Losordo DW, Kishore R (2006) IL-10-induced TNF-alpha mRNA 
destabilization is mediated via IL-10 suppression of p38/MAP kinase activation 
and inhibition of HuR expression. FASEB 20:112-114. 
Rocher C, Singla R, Singal P, Parthasarathy S, Singla DK (2011) Bone morphogenetic 
protein 7 polarizes THP-1 cells into M2 macrophages. Can J Physiol Pharmacol 
90:947-51. 
Saydah S, Loria C, Eberhardt M, Brancati F (2001) Subclinical states of glucose 
intolerance and risk of death in the U.S. Diabetes Care 24:447–453. 
Schwartzbauer G and Robbins J (2001) The Tumor Suppressor Gene PTEN Can 
Regulate Cardiac Hypertrophy and Survival. J Biol Chem 278:35786-35793. 
Singla DK, Lyons GE, Kamp TJ (2007) Transplanted embryonic stem cells following 
mouse myocardial infarction inhibit apoptosis and cardiac remodeling. Am J 
Physiol 293:H1308−H1314. 
Stith R, Luo J (1994) Endocrine and carbohydrate responses to interleukin-6 in vivo. 
Circulatory Shock 44:210-215. 
38 
Stolar M (2010) Glycemic control and complications in type 2 diabetes mellitus. Am J 
Med 123: S3–11. 
Xu J, Zhao Y, Wang J, Yuan Z, Zhang T (2010) Effects of mouse recombinant bone 
morphogenetic protein-7 transfection on cell apoptosis, NF-κB, and downstream 
genes in cultured primary cardiomyocytes after simulated ischemia and 
reperfusion injury. J Cardiovasc Pharmacol 56:69-77. 
Yin D, Tao J, Lee DD, Shen J, Hara M, Lopez J, Kuznetsov A, Philipson LH, Chog AS. 
(2006) Recovery of Islet β-Cell Function in Streptozotocin- Induced Diabetic Mice 
An Indirect Role for the Spleen. Diabetes 12:3256-3263.  
Zeisberg M (2006) Bone morphogenetic protein-7 and the kidney: current concepts and 
questions. Nephrol Dial Transplant 21:568-573. 
Zheng XY, Wang YP, Cantley J, Iseli TJ, Molero JC, Hegarty BD, Kraegen EW, Ye Y, 
Ye JM (2012) Oleanolic Acid Reduces Hyperglycemia beyond Treatment Period 
with Akt/FoxO1-Induced Suppression of Hepatic Gluconeogenesis in Type-2 
Diabetic Mice. Plos One7:e42115. 
 
